Jobs
-
Impel NeuroPharma has announced that 3M New Ventures (3M NV) led the investment in its $12 million Series B financing round to raise money for commercialization of Impel’s Precision Olfactory Delivery (POD) platform. Impel recently… Read more . . .
-
Grupo Ferrer, which is partnered with Alexza Pharmaceuticals on Adasuve Staccato loxapine inhalation powder in the EU, Latin America, CIS nations, Middle East, North Africa, and parts of Asia, has reiterated its support for the… Read more . . .
-
Hovione has announced that Kristine Senft has joined the company as VP, Sales and Marketing and will succeed Dave Hoffman as VP, Sales and Business Development upon his retirement in April 2016. Senft, who was… Read more . . .
-
Eli Lilly has acquired worldwide rights to Locemia Solution’s intranasal glucagon, which is in Phase 3 development for the treatment of severe hypoglycemia in diabetics who use insulin, the two companies said. The dry powder… Read more . . .
-
OptiNose has announced the closing of a financing round of up to $30M, which it plans to use for continued development and commercialization of its OPN-375 intranasal fluticasone as well as for additional pipeline products.… Read more . . .
-
InCarda Therapeutics has been issued patents in the United States, Australia and Canada covering the company’s inhaled flecainide for the treatment of paroxysmal atrial fibrillation (PAF), the company said. Those patents include US patent No.… Read more . . .
-
3M Drug Delivery Systems and Impel NeuroPharma have announced that the two companies will collaborate on development and commercialization of Impel’s Precision Olfactory Delivery (POD) platform for intranasal delivery of drugs to the central nervous… Read more . . .
-
Serendex Pharmaceuticals has announced that data from a Phase 1 randomized, double blind, placebo controlled single ascending dose/multiple ascending dose trial showed that Molgradex inhaled GM-CSF (molgramostim) was well tolerated at all dose levels. No… Read more . . .
-
A Phase 2 study of Invion’s INV102 inhaled nadolol showed that smokers using the therapy were much more likely to stop smoking or significantly reduce the number of cigarettes they smoked than those using a… Read more . . .
-
Celdara Medical and Pulmatrix have been awarded a 3-year $1.7 million Fast Track Small Business Innovation Research grant from the National Heart Lung and Blood Institute (NHLBI) for development of an inhaled therapy for the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland